Medically reviewed by Archana Sharma, DO Diagnosing multiple myeloma, also referred to as myeloma, is often a complex process. While this rare blood cancer can cause many complications, it can't be ...

Multiple myeloma is predominantly a disease of the elderly, with the median age at diagnosis about 70; one-third of patients ...

Discover the current challenges in diagnosing multiple myeloma and how advances in diagnostic technologies could help ...

The FDA’s approval of linvoseltamab for adults with heavily pretreated relapsed/refractory multiple myeloma marks a significant advance, with Sundar Jagannath, MBBS, emphasizing its high response ...

Panelists discuss how preparing multiple myeloma patients for treatment involves structured education, emotional support, and ...

The first sign of multiple myeloma varies by person and may not occur until a later stage of the disease. Learn how to ...

Researchers at Uppsala University have identified a promising therapeutic approach for the challenging blood cancer multiple ...

Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing ...

Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how incidental back pain led to an unexpected cancer diagnosis, the initial ...

In this video, Sham Mailankody, MBBS, highlights data from a study of carfilzomib, lenalidomide and dexamethasone, with or without daratumumab, for patients with newly diagnosed multiple myeloma.“Four ...

Background: Bispecific antibodies (BsABs) have emerged as promising therapeutic modalities for relapsed/refractory multiple myeloma (RRMM), with three FDA-approved drugs currently available: ...

Johnson & Johnson (JNJ) stock in focus as Darzalex SC developed with Halozyme (HALO) and Genmab (GMAB) receives EU nod for ...